Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing (NutriAge)
NUTRI.AGE: DEVELOPMENT OF SMART FOOD/NUTRACEUTICAL SOLUTIONS DEDICATED TO CARDIOMETABOLIC DISORDERS IN AGEING
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Flavia Prodam, MD PhD
- Numero di telefono: +39-0321-660693
- Email: flavia.prodam@med.uniupo.it
Luoghi di studio
-
-
-
Novara, Italia, 28100
- Reclutamento
- SCDU Endocrinology. AOU Ospedale Maggiore della Carità
-
Contatto:
- Flavia MD Prodam, MD PhD
- Numero di telefono: 0321660693
- Email: flavia.prodam@med.uniupo.it
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Patients of either gender, over 65 years of age, able to understand the protocol procedures.
- Known cardiovascular disease
- Prediabetes or type 2 diabetes mellitus with HbA1c < 7.0% on diet alone or metformin.
Exclusion Criteria:
- Age under 65
- Previous diagnosis of type 2 diabetes mellitus already undergoing drug therapy (except metformin)
- Contraindications such as allergy to product components
- Obesity secondary to diseases: genetic (Prader-Willi syndrome, Down syndrome); metabolic and endocrine (Cushing's syndrome, hypothyroidism)
- Endocrine or liver disease or clinical evidence of chronic disease or gastrointestinal disorders or malabsorption disorders
- History of adrenal adenoma or secondary arterial hypertension due to renal/adrenal causes
- Arterial hypertension treated with an ACE inhibitor or ARB
- Previous bariatric surgery
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Placebo
Participants will receive a placebo for 60 days to allow comparison of the results with those observed in the intervention arm.
Participants will take one placebo capsule once daily in the morning, on an empty stomach.
|
Participants will receive a probiotic for 60 days to allow comparison of the results with those observed in the placebo arm.
Participants will take one probiotic capsule once daily in the morning, on an empty stomach.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Blood glucose assessment with OGTT test and FGM
Lasso di tempo: 4 months
|
Blood glucose and insulin tests at 0', 30', 60', 90', 120' minutes every 30 minutes Blood glucose monitoring at home
|
4 months
|
|
Pressure assessment
Lasso di tempo: 4 months
|
Blood pressure is assessed during the visit at time 0 and after 60 days Filling out a blood pressure diary at home
|
4 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Anthropometric measurements
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
Weight is assessed in Kg with the use of the bioimpedance balance.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
the height is measured in cm through a wall altimeter
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
the BMI (body mass index) is calculated by making the ratio of the weight to the square of the height.
normal weight is defined as 18.5-24.9
kg/m², overweight as 25.0-29.9
kg/m², and obesity as ≥30.0 kg/m
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Anthropometric measurements
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
Waist, hip, arm, and calf circumferences are measured using an inelastic measuring tape.
Waist circumference is also assessed as an indicator of abdominal obesity and increased cardiometabolic risk, using the following reference cut-off values for European populations: ≥94 cm in men and ≥80 cm in women.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Adherence level to the Western diet with European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaires
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
Assessed with the use of questionnaire.
EPIC is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition.
This is a qualitative questionnaires and not quantitative.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Adherence level to the Western diet with 24h recall questionnaires
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
Assessed with the use of questionnaires.
24h recall questionnaire is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition.
This is a qualitative questionnaires and not quantitative.
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Advanced glycation end products quantification
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
AGE levels will be measured using skin fluorescence, using the "AGE reader mu" device (range from 1.3 to 5 level of AGEs respect to the patient's age)
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Endogenous and exogenous AGEs plasma quantification
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
AGEs will also be assessed at the plasma level in free form (ELISA, fluorescence assay) or bound to hemoglobin (HbA1c clinical practice test), both measured in pg/mL
|
evaluation of weight and body composition through study completion, an average of 4 months
|
|
Soluble RAGEs plasma quantification
Lasso di tempo: evaluation of weight and body composition through study completion, an average of 4 months
|
RAGEs will also be assessed at the plasma level in solule form (ELISA) measured in pg/mL
|
evaluation of weight and body composition through study completion, an average of 4 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Flavia Prodam, MD PhD, AOU Maggiore della Carita
Pubblicazioni e link utili
Pubblicazioni generali
- [1] Vadim N. GladyshevAging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes,06 April 2016 https://doi.org/10.1111/acel.12480. [2] Guo, J., Huang, X., Dou, L. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct Target Ther 7, 391 (2022). https://doi.org/10.1038/s41392-022-01251-0. [3] http://dati-anziani.istat.it/Index.aspx [4] https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?id=3074 [5] Ilse Bloom, Mark Edwards, Karen A. Jameson, Holly E. Syddall, Elaine Dennison, Catharine R. Gale, Janis Baird, Cyrus Cooper, Avan Aihie Sayer, Sian Robinson, Influences on diet quality in older age: the importance of social factors, Age and Ageing, Volume 46, Issue 2, March 2017, Pages 277-283, https://doi.org/10.1093/ageing/afw180 [6] https://doi.org/10.1093/ageing/afw180Ragonnaud, E., Biragyn, A. Gut microbiota as the key controllers of "healthy" aging of elderly people. Immun Ageing 18, 2 (2021). https://doi.org/10.1186/s12979-020-00213-w [7] Nuria Salazar, Lorena Valdés-Varela, Sonia González, Miguel Gueimonde & Clara G. de los Reyes-Gavilán (2017) Nutrition and the gut microbiome in the elderly, Gut Microbes, 8:2, 82- 97, DOI: 10.1080/19490976.2016.1256525 [8] Białecka-Dębek, A.; Granda, D.; Szmidt, M.K.; Zielińska, D. Gut Microbiota, Probiotic Interventions, and Cognitive Function in the Elderly: A Review of Current Knowledge. Nutrients 2021, 13, 2514. https://doi.org/10.3390/nu13082514 [9] Hutchinson, A.N.; Bergh, C.; Kruger, K.; Sűsserová, M.; Allen, J.; Améen, S.; Tingö, L. The Effect of Probiotics on Health Outcomes in the Elderly: A Systematic Review of Randomized, Placebo-Controlled Studies. Microorganisms 2021, 9, 1344. https://doi.org/10.3390/microorganisms9061344 [10] ALE, Elisa C.; BINETTI, Ana G. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Frontiers in Microbiology, 2021, 12: 631254. [11] Wu, H.; Chiou, J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients 2021, 13, 2878. https://doi.org/10.3390/nu13082878 [12] Kiersnowska K, Jakubczyk A. Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy. Foods. 2022 Oct 21;11(20):3300. doi: 10.3390/foods11203300. PMID: 37431048; PMCID: PMC9602117. [13] Alexander R, Khaja A, Debiec N, Fazioli A, Torrance M, Razzaque MS. Health-promoting benefits of lentils: Anti-inflammatory and anti-microbial effects. Curr Res Physiol. 2024 Mar 5;7:100124. doi: 10.1016/j.crphys.2024.100124. PMID: 38501131; PMCID: PMC10945126. [14] Rezvankhah A, Yarmand MS, Ghanbarzadeh B, Mirzaee H. Development of lentil peptides with potent antioxidant, antihypertensive, and antidiabetic activities along with umami taste. Food Sci Nutr. 2023 Feb 27;11(6):2974-2989. doi: 10.1002/fsn3.3279. PMID: 37324857; PMCID: PMC10261806. [15] Nicola Faccilongo, Giustina Pellegrini, Piermichele La Sala, Economia circolare e scarti nelle filiere agroalimentari: prima indagine esplorativa sullo stato dell'arte, in
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie metaboliche
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Malattie nutrizionali e metaboliche
- Diabete mellito, tipo 2
- Malattia cardiovascolare
- Stato prediabetico
- Integratori dietetici
- Cibo
- Dieta, cibo e nutrizione
- Fenomeni fisiologici
- Cibo e bevande
- Probiotici
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CE070/2025
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .